血清肿瘤标志物对肺癌患者支气管镜活检病理组织学分型的预测价值

doi:10.11904/j.issn.1002-3070.2022.04.005

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (4): 316-322.doi: 10.11904/j.issn.1002-3070.2022.04.005

血清肿瘤标志物对肺癌患者支气管镜活检病理组织学分型的预测价值

孙伟玲, 张明辉, 吴华星, 赵艳滨

哈尔滨医科大学附属肿瘤医院腔镜科(哈尔滨 150081)

收稿日期:2022-04-28 修回日期:2022-06-09 出版日期:2022-08-28 发布日期:2022-08-29
通讯作者: 赵艳滨,E-mail:zhaoyanbin1978@sina.com
作者简介:孙伟玲,女,(1987-),硕士,主治医师,从事肺癌临床诊疗的研究。
基金资助:
北京医学奖励基金会项目(编号:YXJL-2020-0983-0846)

Predictive value of serum tumor markers in histopathological types of bronchoscopy biopsy in patients with lung cancer

SUN Weiling, ZHANG Minghui, WU Huaxing, ZHAO Yanbin

Department of Endoscopy,Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2022-04-28 Revised:2022-06-09 Online:2022-08-28 Published:2022-08-29

摘要/Abstract

摘要： 目的探讨血清肿瘤标志物水平与支气管镜活检组织病理学分型的关系。方法本研究纳入2013年1月—2018年12月于哈尔滨医科大学附属肿瘤医院行支气管镜下活检病理检查,且完成相关血清肿瘤标志物(SCCA、CYFRA21-1、CEA、CA125、NSE)检测的356例肺癌患者(140例小细胞癌、122例鳞状细胞癌、94例腺癌),对患者进行回顾性分析。结果在支气管镜活检的肺癌患者中,五种血清肿瘤标志物的组合(SCCA+CYFRA21-1+CEA+CA125+NSE,AUC=0.948,P＜0.001)对小细胞肺癌与非小细胞肺癌的辅助诊断价值更高;三种(SCC+CEA+NSE,AUC=0.901,P＜0.001)或四种(SCC+CYFRA21-1+CEA+NSE,AUC=0.901,P＜0.001)标志物联合鉴别鳞状细胞癌与腺癌准确性更高;而在非小细胞肺癌中鉴别鳞状细胞癌与腺癌,三种标志物组合(SCCA+CEA+CA125,AUC=0.831,P＜0.001)的价值更高。结论对于不同病理分型的肺癌患者,不同血清肿瘤标志物组合对支气管镜下活检病理的分型有一定的辅助诊断价值。

关键词: 肺癌, 肿瘤标志物, 支气管镜, 活检病理

Abstract: Objective The aim of the study was to investigate the relationship between the serum levels of tumor markers and histopathological types of bronchoscopy biopsy.Methods A retrospective study was performed in 356 lung cancer patients who underwent bronchoscopy biopsy at Harbin Medical University Cancer Hospital from January 2013 to December 2018 and completed the detection of related serum tumor markers(SCCA,CYFRA21-1,CEA,CA125 and NSE).Patients with lung cancer(140 small cell carcinoma,122 squamous cell carcinoma and 94 adenocarcinoma)were retrospectively analyzed.Results In lung cancer patients with bronchoscopy biopsy,the combination of five serum tumor markers(SCCA+CYFRA21-1+CEA+CA125+NSE,AUC=0.948,P＜0.001)had a high value in assisting the diagnosis of small cell carcinoma and non-small cell lung cancer;three(SCC+CEA+ NSE,AUC=0.901,P＜0.001)or four(SCC+CYFRA21-1+CEA+NSE,AUC=0.901,P＜0.001)markers combined to distinguish squamous cell carcinoma and adenocarcinoma were more accurate.The value of the three marker combination(SCCA+CEA+CA125,AUC=0.831,P＜0.001)had a high value of diagnosis.Conclusion For lung cancer patients with different pathological types,the combination of different serum tumor markers has certain auxiliary diagnostic value for pathological types under bronchoscopy biopsy.

Key words: Lung cancer, Tumor markers, Bronchoscopy, Biopsy pathology

中图分类号:

R734

孙伟玲, 张明辉, 吴华星, 赵艳滨. 血清肿瘤标志物对肺癌患者支气管镜活检病理组织学分型的预测价值[J]. 实用肿瘤学杂志, 2022, 36(4): 316-322.

SUN Weiling, ZHANG Minghui, WU Huaxing, ZHAO Yanbin. Predictive value of serum tumor markers in histopathological types of bronchoscopy biopsy in patients with lung cancer[J]. Journal of Practical Oncology, 2022, 36(4): 316-322.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.04.005

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I4/316

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 中华人民共和国国家卫生健康委员会.常见肿瘤诊疗指南(2022版)[S].原发性肺癌诊疗指南,2022,74.
3 Ferrigno D,Buccheri G,Biggi A.Serum tumour markers in lung cancer:history,biology and clinical applications[J].Eur Respir J,1994,7(1):186-197.
4 Kagohashi k,Satoh H,Ishikawa H,et al.Are-evaluation of squamous cell carcinoma antigen(SCC)as a serum marker for non-small cell lung cancer[J].Med Oncol,2008,25(2):187-189.
5 van der Gaast A,Schoenmakers CH,Kok TC,et al.Evaluation of a new tumour marker in patients with non-small-cell lung cancer:Cyfra 21.1[J].Br J Cancer,1994,69(3):525-528.
6 Yan HJ,Wang RB,Zhu KL,et al.Cytokeratin 19 fragment antigen 21-1 as an independent predictor for definitive chemoradiotherapy sensitivity in esophageal squamous cell carcinoma[J].Chin Med J(Engl),2012,125(8):1410-1415.
7 Tahanovich AD,Kauhanka NN,Prohorova VI,et al.Predicting the risk of tumor progression in patients with early stages of adenocarcinoma and squamous cell lung carcinoma based on laboratory parameters[J].Biomed Khim,2021,67(6):507-517.
8 Hammarstrom S.The carcinoembryonic antigen(CEA)family:structures,suggested functions and expression in normal and malignant tissues[J].Semin Cancer Biol,1999,9(2):67-81.
9 Chen ZQ,Huang LS,Zhu B.Assessment of seven clinical tumor markers in diagnosis of non-small-cell lung cancer[J].Dis Markers,2018,2018:9845123.
10 Li Z,Zhao J.Clinical efficacy and safety of crizotinib and alectinib in ALK-positive non-small cell lung cancer treatment and predictive value of CEA and CA125 for treatment efficacy[J].Am J Transl Res,2021,13(11):13108-13116.
11 Jørgensen LG,Osterlind K,Genollá J,et al.Serum neuron-specific enolase(S-NSE)and the prognosis in small-cell lung cancer(SCLC):a combined multivariable analysis on data from nine centres[J].Br J Cancer,1996,74(3):463-467.
12 Pastor A,Menéndez R,Cremades MJ,et al.Diagnostic value of SCC,CEA and CYFRA 21.1 in lung cancer:a Bayesian analysis[J].Eur Respir J,1997,10(3):603-609.
13 Tumour markers in lung cancer:EGTM recommendations.European Group on Tumour Markers[J].Anticancer Res,1999,19(4A):2817-2819.
14 Peladan F,Monteil H.Gas chromatographic study of volatile fatty acids produced by 14 species of Pseudomonas[J].Ann Microbiol(Paris),1984,135(3):399-410.
15 Xu LH,Su ZM,Xie BS.Diagnostic value of conventional tumor markers in young patients with pulmonary nodules[J].J Clin Lab Anal,2021,35(9):23912.
16 Robert CT,Haycock PC,Relton CL,et al.The causal relevance of body mass index in different histological types of lung cancer:A Mendelian randomization study[J].Sci Rep,2016,6:31121.
17 Doll R,Peto R.Cigarette smoking and bronchial carcinoma:dose and time relationships among regular smokers and lifelong non-smokers[J].J Epidemiol Community Health,1978,32(4):303-313.
18 Lee PN,Forey BA.Indirectly estimated absolute lung cancer mortality rates by smoking status and histological type based on a systematic review[J].BMC Cancer,2013,13:189.
19 Brooke T,Meredith G,Lisa WL,et al.Capturing acute toxicity data during lung radiotherapy by using a patient-reported assessment tool[J].Clin Lung Cancer,2013,14(2):108-112.
20 Seligson MT,Surowiec SM.Superior Vena Cava Syndrome,Essays in StatPearls[OL](Treasure Island(FL):StatPearls Publishing,2022).
21 Li JL,Chen YQ,Wang XD,et al.The value of combined detection of CEA,CYFRA21-1,SCC-Ag,and pro-GRP in the differential diagnosis of lung cancer[J].Transl Cancer Res,2021,10(4):1900-1906.
22 Wu H,Wang Q,Liu Q,et al.The serum tumor markers in combination for clinical diagnosis of lung cancer[J].Clin Lab,2020,66(3):10.
23 Mehta A,Parkash A,Bhatia M.Cross-sectional study to establish the utility of serum tumor markers in the diagnosis of lung cancer[J].Asian Pac J Cancer Prev,2021,22(8):2569-2576.
24 Ouyang RR,Wu SJ,Zhang B,et al.Clinical value of tumor-associated antigens and autoantibody panel combination detection in the early diagnostic of lung cancer[J].Cancer Biomark,2021,32(3):401-409.
25 Li Q,Sang S.Diagnostic value and clinical significance of combined detection of serum markers CYFRA21-1,SCC Ag,NSE,CEA and ProGRP in non-small cell lung carcinoma[J].Clin Lab,2020,66(11):10.

[1]	李鑫林, 周金意, 韩仁强, 蔡波, 徐红, 韩颖颖. 2013—2017年南通市肺癌流行病学特征分析[J]. 实用肿瘤学杂志, 2022, 36(4): 304-309.
[2]	温晓星, 刘大海, 吴学辉, 王炳平, 房涛. 敲减骨桥蛋白对吉非替尼耐药的非小细胞肺癌PC9细胞凋亡的研究[J]. 实用肿瘤学杂志, 2022, 36(4): 310-315.
[3]	董琳, 刘欣, 鲁海玲. 晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 351-355.
[4]	张浩, 杨新官, 何涌. 肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(3): 214-219.
[5]	肖海帆, 颜仕鹏, 李佶刚, 石朝晖, 邹艳花, 许可葵, 廖先珍. 湖南省2017—2018年肺癌低剂量螺旋CT筛查结果和依从性分析[J]. 实用肿瘤学杂志, 2022, 36(2): 99-104.
[6]	张梦茹, 曹德东, 戈伟. 恩度静脉持续泵入与滴注联合含铂双药方案化疗治疗晚期非小细胞肺癌的疗效与安全性比较[J]. 实用肿瘤学杂志, 2022, 36(1): 20-25.
[7]	罗雯, 贾莉, 张佳文, 王冬杰, 孔英君. circRNA MYO1C对肺癌细胞自噬和肿瘤干细胞分化的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 500-505.
[8]	商昌权, 李国东, 魏九峰, 刘明. MCM蛋白在消化系统肿瘤的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 431-435.
[9]	吴长帅, 张宝慧, 高正莲, 张校望, 王坤. 丙泊酚抗肿瘤作用及分子机制在肺癌中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 480-484.
[10]	汪叶, 尚乃舰. 影像组学在非小细胞肺癌诊疗中的应用进展[J]. 实用肿瘤学杂志, 2021, 35(5): 485-488.
[11]	任思颖, 陈杨, 石青萍, 朱云芳, 文洪梅. 云南省肿瘤登记地区2011—2016年肺癌发病和死亡特征及时间趋势[J]. 实用肿瘤学杂志, 2021, 35(4): 332-338.
[12]	魏东华, 马艳玲, 张娟, 尹惠萍, 张小鹏, 张愉涵, 代敏, 钱立庭. 2014-2016年合肥市城市居民肺癌筛查率及筛查结果分析[J]. 实用肿瘤学杂志, 2021, 35(3): 231-236.
[13]	王俊美, 潘慧卿, 李婧铱, 贾迪, 赵炜明, 吕昌莲. MT2-MMP在Ⅱ期肺腺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2021, 35(3): 243-247.
[14]	尹蕾, 杨旭东, 杨悦, 牛星鉴, 周晓平, 姬宏飞, 王一然. 中性粒细胞与淋巴细胞比值在非小细胞肺癌患者预后评估中的临床意义及相关机制研究[J]. 实用肿瘤学杂志, 2021, 35(2): 117-124.
[15]	焦志云, 杜芳, 何玲, 袁保锋. 动态对比增强磁共振成像对肺癌纵隔淋巴结转移的初步研究[J]. 实用肿瘤学杂志, 2021, 35(2): 142-147.

血清肿瘤标志物对肺癌患者支气管镜活检病理组织学分型的预测价值

Predictive value of serum tumor markers in histopathological types of bronchoscopy biopsy in patients with lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价